Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SALL4 | Q9UJQ4 | 12/20 | 0.76 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.56 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 5/20 | 0.53 |
| ▸ | TAF1 | P21675 | 1/20 | 0.53 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20889797 | 0.86 | SALL4 (1.00) | SALL4TRIM24TRIM33BRD4TAF1 | |
| SCHEMBL12781599 | 0.81 | ADRA1B (0.71) | SALL4BRD4TAF1TAF1LADRA1B | |
| SCHEMBL31193266 | 0.77 | BRD4 (0.66) | SALL4BRD4TAF1TAF1LADRA1B | |
| SCHEMBL6642617 | 0.77 | SALL4 (0.47) | SALL4BRD4TAF1TAF1LKDM4E | |
| SCHEMBL20889522 | 0.75 | SALL4 (0.56) | SALL4TRIM24TRIM33BRD4TAF1 | |
| SCHEMBL20889821 | 0.75 | SALL4 (0.55) | SALL4BRD4TAF1TAF1LADRA1B | |
| SCHEMBL16424680 | 0.74 | BRD4 (0.65) | SALL4BRD4TAF1TAF1LADRA1B | |
| SCHEMBL20889419 | 0.74 | BRD4 (0.56) | SALL4TRIM24TRIM33BRD4TAF1 | |
| SCHEMBL20889785 | 0.74 | SALL4 (0.54) | SALL4BRD4TAF1TAF1LADRA1B | |
| SCHEMBL20889766 | 0.73 | BRD4 (0.55) | SALL4BRD4TAF1TAF1LADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218382-B1 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2004-01-28 | — | — | EP | claimed |
| US-6638933-B2 | Analgesics | GRUENENTHAL GMBH (DE) | 2003-10-28 | — | — | US | claimed |
| JP-2003511451-A | — | — | 2003-03-25 | — | — | JP | claimed |
| EP-1218382-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001027111-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| EP-1218382-B1 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2004-01-28 | — | — | EP | disclosed |
| US-6638933-B2 | Analgesics | GRUENENTHAL GMBH (DE) | 2003-10-28 | — | — | US | disclosed |
| US-20030018032-A1 | Bicyclic imidazo-3-yl-amine derivatives | GRUENENTHAL GMBH | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018032-A1 | Bicyclic imidazo-3-yl-amine derivatives | OPRK1, IPO4, GRIN3A | SALL4 1996/4885TRIM24 439/4885TRIM33 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.